Ayla Kouli, Damascus University, Damascus, Syria, discusses the hormone receptor expression patterns in Syrian patients with breast cancer. Findings reveal that more than half of cases were HER2+ or triple-negative, suggesting poorer prognoses, and the majority were hormone receptor-positive (HR+)/HER2-. The study highlights the impact of Syria’s protracted war on healthcare infrastructure and cancer registry practices, emphasizing the need for improved data collection and targeted interventions to address breast cancer outcomes in this population. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
